{"id":618,"date":"2015-07-16T11:57:39","date_gmt":"2015-07-16T06:27:39","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=618"},"modified":"2023-08-17T15:02:35","modified_gmt":"2023-08-17T09:32:35","slug":"delveinsights-oncology-based-reports-2015","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015","title":{"rendered":"DelveInsight\u2019s Oncology based Reports, 2015"},"content":{"rendered":"<h6 style=\"text-align: justify;\">DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to this, our research expertise provides our clients with up to date information of market till the date on which order is placed.<\/h6>\n<h6 style=\"text-align: justify;\"><\/h6>\n<h6 style=\"text-align: justify;\">Limited alternatives and high unmet needs have made global cancer market to rise unexpectedly and is presumed to reach\u00a0around $\u00a0100-110 billion by 2020. Recently companies have come up with new targeted therapies involving <span style=\"color: #000000;\"><strong>Immunotherapy.<\/strong> <\/span>It is a major technological <span style=\"color: #000000;\"><strong>breakthrough in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis<\/strong> <\/span>of the disease which are expected to deliver improved results in terms of safety and efficacy.<\/h6>\n<p>The current Oncology market is steered by companies such as <span style=\"color: #000000;\"><strong>Roche <\/strong>for <strong>Avastin, Herceptin &amp; Rituxan, Novartis <\/strong>for<strong> Gleevac\/Glivec<\/strong> and<strong> Celgene<\/strong> for <strong>Revlimid<\/strong>.<\/span><\/p>\n<p style=\"text-align: left;\"><span style=\"color: #993300;\"><strong>DelveInsight <\/strong><\/span>has made strong presence in Oncology market with <span style=\"color: #993300;\"><strong><span style=\"color: #993300;\">100+<\/span> <\/strong><\/span>Reports on Oncology based <span style=\"color: #993300;\"><strong><span style=\"color: #993300;\">Indications &amp; Mechanism of Action (MOA).<\/span> <\/strong><\/span>DelveInsight\u2019s Reports on <span style=\"color: #993300;\"><strong>gene therapy, PD-1\/PDL-1, Antibody-Drug Conjugate (ADC) &amp; CAR-T <\/strong><\/span>provides assessment over <span style=\"color: #993300;\"><span style=\"color: #000000;\">advancement in technologies<\/span>, <span style=\"color: #000000;\">market trend, partnering &amp; licensing opportunities, pipeline scenario and competitive landscape<\/span><span style=\"color: #000000;\">.<\/span><\/span> In addition, the Oncology Reports will help to identify the key players of market and the <strong><span style=\"color: #000000;\">potential market movers and<\/span> barriers<\/strong>. After getting great response and feedback now we are planning to launch reports on <span style=\"color: #993300;\"><strong>Stem Cell Oncology<\/strong>, <strong>Bruton&#8217;s Tyrosine Kinase (BTK) Inhibitors, TIM3, OX40, and LAG3<\/strong>.<\/span><\/p>\n<p>DelveInsight\u2019s Oncology reports help companies in understanding Oncology<span style=\"color: #000000;\"> <strong>market dynamics<\/strong><\/span> and therefore giving opportunities for<span style=\"color: #000000;\"> <strong>strategic alliance<\/strong> <\/span>that will result in <span style=\"color: #000000;\"><strong>market penetration<\/strong><\/span> and <strong><span style=\"color: #000000;\">enhancement of portfolios with optimal<\/span> <span style=\"color: #000000;\">investment and maximal return<\/span><\/strong>. In addition, reports will assuage companies to detect <span style=\"color: #000000;\"><strong>specific tumors<\/strong><\/span>, determine <strong>g<span style=\"color: #000000;\">enetic predisposition<\/span><\/strong> and <span style=\"color: #000000;\"><strong>biological response to cancer therapy<\/strong>.<\/span><\/p>\n<p>For more information on our Oncology Reports email us at <a href=\"mailto:info@delveInsight.com\">info@delveInsight.com<\/a><\/p>\n<p>About Us:<\/p>\n<p>DelveInsight is a leading <span style=\"color: #000000;\"><strong>Business Consulting and Market Research Firm<\/strong>.\u00a0<\/span> We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this, DelveInsight also deals in providing <span style=\"color: #000000;\"><strong>custom research services<\/strong><\/span> in coherence with interest area of the clients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to this, our research expertise provides our clients with up to date information of market till the date on which order is placed. Limited alternatives and high [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":619,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[78,132,204,258,428,457,477,545],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-618","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-antibody-drug-conjugates","tag-btk-inhibitors","tag-delveinsight","tag-gene-therapy","tag-oncology-reports","tag-pd-1pdl-1","tag-pipeline","tag-stem-cell-oncology","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Oncology Market Trends, Analyisis and Forecast Reports | DelveInsight<\/title>\n<meta name=\"description\" content=\"DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications &amp; Mechanism of Action (MOA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncology Market Trends, Analyisis and Forecast Reports | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications &amp; Mechanism of Action (MOA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-16T06:27:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-17T09:32:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"227\" \/>\n\t<meta property=\"og:image:height\" content=\"65\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oncology Market Trends, Analyisis and Forecast Reports | DelveInsight","description":"DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015","og_locale":"en_US","og_type":"article","og_title":"Oncology Market Trends, Analyisis and Forecast Reports | DelveInsight","og_description":"DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA).","og_url":"https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-07-16T06:27:39+00:00","article_modified_time":"2023-08-17T09:32:35+00:00","og_image":[{"width":227,"height":65,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015","url":"https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015","name":"Oncology Market Trends, Analyisis and Forecast Reports | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg","datePublished":"2015-07-16T06:27:39+00:00","dateModified":"2023-08-17T09:32:35+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA).","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/delveinsights-oncology-based-reports-2015#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg","width":227,"height":65},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/09022438\/delveinsight_logo.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">BTK Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncology reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1\/PDL-1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Stem cell Oncology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/span>","<span class=\"advgb-post-tax-term\">BTK Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Oncology reports<\/span>","<span class=\"advgb-post-tax-term\">PD-1\/PDL-1<\/span>","<span class=\"advgb-post-tax-term\">Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Stem cell Oncology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jul 16, 2015","modified":"Updated on Aug 17, 2023"},"absolute_dates_time":{"created":"Posted on Jul 16, 2015 11:57 am","modified":"Updated on Aug 17, 2023 3:02 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=618"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/618\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/619"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=618"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=618"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}